source
- AstraZeneca's Etcamah fails late-stage trial for early-stage breast cancer useAstraZeneca announced that its newly approved breast cancer therapy, Etcamah, did not meet its primary goals in a pivotal study aimed at expanding the drug's label. The trial evaluated Etcamah in…
- Akeso and Summit report survival advantage for PD-1xVEGF combo over KeytrudaAt the American Society of Clinical Oncology (ASCO) 2026 meeting, Akeso Biopharma and its partner Summit Therapeutics announced new survival results for their experimental PD‑1×VEGF bispecific anti…